What is the ROE (Return on Equity) of Genexine this year?
The ROE of Genexine this year is -0.24 undefined.
Genexine ROE 2025
Genexine ROE
-0.24
Ticker
095700.KQ
ISIN
KR7095700001
In 2025, Genexine's return on equity (ROE) was -0.24, a 7.98% increase from the -0.23 ROE in the previous year.
Genexine Aktienanalyse
What does Genexine do?
Genexine Inc is a leading biotechnology company focused on developing therapies for serious diseases. The company was founded in Korea in 1999 and has since undergone impressive development. Genexine ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding Genexine's Return on Equity (ROE)
Genexine's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing Genexine's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
Genexine's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in Genexine’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about Genexine stock
How has the Return on Equity (ROE) of Genexine developed compared to the previous year?
The ROE of Genexine has increased by 7.98% increased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of Genexine?
A high ROE indicates that Genexine generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of Genexine?
A low ROE can indicate that Genexine is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of Genexine affect the company?
A change in ROE (Return on Equity) of Genexine can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of Genexine?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of Genexine?
Some factors that can influence Genexine's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does Genexine pay?
Over the past 12 months, Genexine paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Genexine is expected to pay a dividend of 0 KRW.
What is the dividend yield of Genexine?
The current dividend yield of Genexine is .
When does Genexine pay dividends?
Genexine pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Genexine?
Genexine paid dividends every year for the past 0 years.
What is the dividend of Genexine?
For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.
In which sector is Genexine located?
Genexine is assigned to the 'Health' sector.
Wann musste ich die Aktien von Genexine kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Genexine from 6/24/2025 amounting to 0 KRW, you needed to have the stock in your portfolio before the ex-date on 6/24/2025.
When did Genexine pay the last dividend?
The last dividend was paid out on 6/24/2025.
What was the dividend of Genexine in the year 2024?
In the year 2024, Genexine distributed 0 KRW as dividends.
In which currency does Genexine pay out the dividend?
The dividends of Genexine are distributed in KRW.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Genexine
Our stock analysis for Genexine Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Genexine Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
